Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 106 Pancreatic Neoplasms 31 Esophageal Neoplasms 17 Esophageal Squamous Cell Carcinoma 11 Biliary Tract Neoplasms 11 Colorectal Neoplasms 10 Cholangiocarcinoma 6 Neoplasm Metastasis 5 Nasopharyngeal Carcinoma 5 Adenocarcinoma 5 Recurrence 4 Head and Neck Neoplasms 4 Gastrointestinal Neoplasms 4 Colonic Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Rectal Neoplasms 3 Advanced Pancreatic Cancer 3 Advanced Gastric Cancer 3 Stage IV Gastric Cancer With Metastasis 2 Neoplasms 2 NSCLC 2 Locally Advanced Gastric Cancer 2 Gastric Cancer Peritoneal Metastases 2 Gastric Adenocarcinoma 2 Gallbladder Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 mCRC 1 Surgically-Created Resection Cavity 1 Squamous Cell Carcinoma of Head and Neck 1

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 Irinotecan 1 HMPL-013 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Fruquintinib × S 1 (combination) × Clear all

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Unknown

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡